Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial
Randomised controlled trialHumansTopical
- Design
- Randomised controlled trial
- Subjects
- 72 adults with eczema on the hands or arms enrolled. 65 completed (32 on the palmitoylethanolamide cream, 33 on the comparator).
- Dose used in the study
- A moisturising cream with 1.5% palmitoylethanolamide (Levagen+), applied twice a day, compared with the same base cream without it
- Duration
- 4 weeks
- What was measured
- Self-assessed eczema severity, the Patient-Oriented Eczema Measure, a quality of life index and an itch rating
What the authors reported
The authors reported lower scores for redness, dryness and the total eczema measure in the palmitoylethanolamide group at week 4 (p < 0.05), with less weeping and less roughness than the comparator. They found no significant difference between the groups in quality of life. No adverse events were reported.
Limits of this study
All outcomes were assessed by the participants, with no examination by a clinician. The authors name this, and the 4-week duration, as limits. Gencor Pacific, which makes Levagen+, supplied the product and the funding.
Source
Entry checked against the article page at the publisher (Karger) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.